- Home
- AVIR vs RDCM Comparison
AVIR vs RDCM Comparison
Compare AVIR & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- RDCM
- Stock Information
- Founded
- AVIR 2012
- RDCM 1985
- Country
- AVIR United States
- RDCM Israel
- Employees
- AVIR N/A
- RDCM N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- RDCM Computer peripheral equipment
- Sector
- AVIR Health Care
- RDCM Technology
- Exchange
- AVIR Nasdaq
- RDCM Nasdaq
- Market Cap
- AVIR 251.7M
- RDCM 223.5M
- IPO Year
- AVIR 2020
- RDCM 1997
- Fundamental
- Price
- AVIR $3.09
- RDCM $12.81
- Analyst Decision
- AVIR Hold
- RDCM Strong Buy
- Analyst Count
- AVIR 1
- RDCM 2
- Target Price
- AVIR $6.88
- RDCM $15.00
- AVG Volume (30 Days)
- AVIR 318.0K
- RDCM 144.8K
- Earning Date
- AVIR 03-03-2025
- RDCM 02-12-2025
- Dividend Yield
- AVIR N/A
- RDCM N/A
- EPS Growth
- AVIR N/A
- RDCM 79.17
- EPS
- AVIR N/A
- RDCM 0.43
- Revenue
- AVIR N/A
- RDCM $61,009,000.00
- Revenue This Year
- AVIR N/A
- RDCM $13.44
- Revenue Next Year
- AVIR N/A
- RDCM $11.00
- P/E Ratio
- AVIR N/A
- RDCM $32.07
- Revenue Growth
- AVIR N/A
- RDCM 18.23
- 52 Week Low
- AVIR $2.75
- RDCM $8.52
- 52 Week High
- AVIR $4.60
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- AVIR 48.26
- RDCM 45.02
- Support Level
- AVIR $3.04
- RDCM $12.58
- Resistance Level
- AVIR $3.25
- RDCM $13.88
- Average True Range (ATR)
- AVIR 0.13
- RDCM 1.04
- MACD
- AVIR 0.01
- RDCM -0.18
- Stochastic Oscillator
- AVIR 54.29
- RDCM 20.15
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.